2023-09-07 14:54:45
The study in which ANSES participated was carried out in collaboration with the United Kingdom Health Safety Agency (UKHSA), the French company Osivax and the Vaccine Formulation Institute, in Switzerland. The results were published in the journal Frontiers in immunology in June 2023.
Promising first tests
Unlike the vaccines currently used once morest Sars-CoV-2, the vaccine tested is as effective once morest the original strain as once morest the Delta and Omicron variants. One of the proofs of its effectiveness on golden hamsters is their weight: it decreased little in hamsters vaccinated then infected with one of the variants. On the contrary, their unvaccinated congeners have lost 5 to 10% of their mass following being infected with the original strain or the Delta variant. In addition, the lungs of vaccinated hamsters show significantly fewer lesions. Finally, the virus replication rate is lower in these animals.
A common protein in sarbecoviruses as a target
The versatility of the vaccine is explained by its design: it targets the nucleocapsid protein (N) of the virus and not the Spike (S) protein, present on the envelope of the virus. The latter, more classically used to quickly develop a vaccine, has a disadvantage: it changes from one variant to another. ” The N protein is conserved between variants of Sars-CoV-2 and more broadly within sarbecoviruses, the subgenus to which the coronaviruses responsible for severe acute respiratory syndrome such as SARS-CoV-1 and SARS-CoV belong. -2. » explains Elodie Monchâtre-Leroy, director of the Anses Rage and Wildlife laboratory, located in Nancy. Present inside the virus, this protein is produced in large quantities when it replicates. Its recognition by cells of the immune system allowseliminate infected cells and prevent the virus from multiplying.
1694274022
#SARSCoV2 #vaccine #path #effective #variants #Handles